Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Priority review
Indication
Keytruda (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer
Therapeutic area
Oncology